SynthesisThe oncologist2025
Gastrointestinal CancerEmerging treatment modalities for gastric cancer with peritoneal metastases: a systematic review.
Synthesis in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Catheter based intraperitoneal chemotherapy using taxane for peritoneal metastases from gastric cancer: from bench to bedside-a narrative review.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Review
- The Role of Diagnostic Laparoscopy in Staging and Treatment Planning of Gastric Cancer: A 400-Patient Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Review
- Prognostic stratification in gastric cancer with peritoneal metastasis: tumor biology and diagnostic modality as a surrogate for disease burden.BMC cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionGastric cancer remains associated with a high mortality, since patients often present with advanced-stage disease such as peritoneal metastases. Treatment options in this setting are limited and mainly consist of palliative systemic therapy.
objectivesThis systematic review aims to summarize emerging therapeutic strategies for patients with peritoneally metastasized gastric cancer in relation to response, toxicity, and survival.
methodsA search was performed in PubMed, EMBASE, and Cochrane database until December 8, 2023. Studies were eligible if they prospectively investigated any form of cancer treatment in adult patients with peritoneally metastasized gastric cancer.
resultsIn total, 25 articles were retrieved from 9 different countries, investigating systemic therapy, intraperitoneal therapy (IP), hyperthermic intraperitoneal chemotherapy (HIPEC) with or without cytoreductive surgery (CRS), and pressurized intraperitoneal aerosol chemotherapy (PIPAC). CRS-HIPEC followed by early postoperative intraperitoneal chemotherapy (EPIC) showed high complication rates and patient drop-out. Median overall survival (OS) ranged from 6.5 to 7.4 months with systemic chemotherapy, 13.0 to 23.9 months with IP chemotherapy, 6.8 to 13.0 months after PIPAC, 11.0 to 19.0 months with CRS-HIPEC, and 9.9 months in elderly with HIPEC alone. Notably, patients with a Peritoneal Cancer Index ≥20 showed median OS ≥13.0 months with IP chemotherapy or HIPEC without CRS.
conclusionFew prospective trials are conducted in patients with peritoneally metastasized gastric cancer. Although IP chemotherapy and CRS-HIPEC show encouraging results in selected cohorts, especially in Asia, current evidence from randomized studies is limited. Further prospective trials are needed to clarify their role alongside the current systemic therapy, including immunotherapy and targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.